At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 118 enrolled
Drug / intervention
AIN457 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy
In Brief
A Phase 3 clinical trial evaluating AIN457 and Placebo for Behcet Disease. Completed, enrolled 118 participants across 49 sites in 17 countries.
Detailed Summary
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet Disease
CountriesEgypt, France, Germany, Greece, Hong Kong, India, Israel, Italy, Jordan, Singapore, South Korea, Spain, Switzerland, Taiwan, Tunisia, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedOct 15, 2009
Enrollment StartOct 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.7 years ago
Interventions
AIN457drug
AIN457drug
Placebodrug